Construction of recombinant vaccinia viruses using PUV-inactivated virus as a helper
- PMID: 11570497
- DOI: 10.2144/01313st07
Construction of recombinant vaccinia viruses using PUV-inactivated virus as a helper
Abstract
Recombinant vaccinia viruses (VVs) are widely used as expression vectors in molecular biology and immunology and are now under evaluation for gene therapy. The current techniques for inserting foreign DNA into the large VV genome are based on either homologous recombination between transfer plasmids and VVgenomes or direct DNA ligation and packaging using replication-deficient poxviruses. Here, we describe efficient new versions of both methods that produce 90%-100% of the recombinant viruses. In the new homologous recombination method, VV DNA "arms" obtained by NotI digestion and intact transfer plasmids were used for co-transfection. In the direct DNA ligation method, foreign DNA was inserted into a unique NotI restriction site of the VVgenome. In both methods, the generation of recombinant viruses was carried out in cells infected with a non-replicating, psoralen-UV (PUV)-inactivated helper VV. The convenience of these new techniques is demonstrated by the construction of recombinant VVs that produce E. coli beta-galactosidase. An important feature of these strategies is that any VV strain can be used as a helper virus after PUV inactivation.
Similar articles
-
Introduction of foreign DNA into the vaccinia virus genome by in vitro ligation: recombination-independent selectable cloning vectors.Virology. 1992 Sep;190(1):522-6. doi: 10.1016/0042-6822(92)91246-q. Virology. 1992. PMID: 1529553
-
Replication-deficient vaccinia virus gene therpay vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells.J Gene Med. 2001 Sep-Oct;3(5):468-77. doi: 10.1002/jgm.205. J Gene Med. 2001. PMID: 11601760
-
Construction of recombinant vaccinia virus: cloning into the thymidine kinase locus.Methods Mol Biol. 2004;269:31-40. doi: 10.1385/1-59259-789-0:031. Methods Mol Biol. 2004. PMID: 15114005 Review.
-
Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant.Cancer Gene Ther. 2000 Jan;7(1):66-73. doi: 10.1038/sj.cgt.7700075. Cancer Gene Ther. 2000. PMID: 10678358
-
Construction and isolation of recombinant vaccinia virus using genetic markers.Methods Mol Biol. 2004;269:15-30. doi: 10.1385/1-59259-789-0:015. Methods Mol Biol. 2004. PMID: 15114004 Review.
Cited by
-
An efficient method for generating poxvirus recombinants in the absence of selection.Viruses. 2011 Mar;3(3):217-32. doi: 10.3390/v3030217. Viruses. 2011. PMID: 21494427 Free PMC article.
-
Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells.Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12415-20. doi: 10.1073/pnas.192420599. Epub 2002 Aug 26. Proc Natl Acad Sci U S A. 2002. PMID: 12196634 Free PMC article.
-
Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer.Gene Ther. 2009 Oct;16(10):1223-33. doi: 10.1038/gt.2009.74. Epub 2009 Jul 9. Gene Ther. 2009. PMID: 19587709 Free PMC article.
-
High-frequency genetic recombination and reactivation of orthopoxviruses from DNA fragments transfected into leporipoxvirus-infected cells.J Virol. 2003 Jul;77(13):7281-90. doi: 10.1128/jvi.77.13.7281-7290.2003. J Virol. 2003. PMID: 12805426 Free PMC article.
-
A novel oncolytic vaccinia virus with multiple gene modifications involved in viral replication and maturation increases safety for intravenous administration while maintaining proliferative potential in cancer cells.PLoS One. 2025 Mar 6;20(3):e0312205. doi: 10.1371/journal.pone.0312205. eCollection 2025. PLoS One. 2025. PMID: 40048445 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources